
Please try another search
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
Name | Age | Since | Title |
---|---|---|---|
Mark Simon | - | 2017 | Member of Advisory Board |
Bhavna Gautam Doshi | 71 | 2014 | Independent Director |
Thennati Rajamannar | 63 | 2007 | Non-Executive Non-Independent Director |
Ferzaan Nariman Engineer | 60 | 2017 | Independent Director |
Robert Jay Spiegel | 75 | 2020 | Independent Director |
Vidhi Dilip Shanghvi | 38 | 2024 | Non-Executive Non-Independent Director |
Venkateswarlu Jasti | 76 | 2025 | Independent Director |
Rekha Gopal Warriar | 68 | 2025 | Independent Director |
Dilip Shantilal Shanghvi | 70 | 2006 | Non-Executive Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review